Scimitar Equity, LLC is an independent equity research firm focused on providing value-added intelligence and insightful investment conclusions on emerging companies demonstrating real progress toward their vision while meeting quarterly expectation.
RegMed Competitive and Market Intelligence 2/22/12, hesitancy is the “byword” of today’s market, stocks struggle for direction, the same issues – traders versus investors
The 6 W’s: Who, what, where, when, why and what of it …
Today’s Gospel: The tone on the trading floor is more … defensive and … negative as the market continues rolling through the week. Although Greece and euro have been the … big news focus, traders are not even considering the RegMed universe … an anemia issue! The problem is most think … an “orderly decline” in equities, macro view> would be healthy for the market following a strong rally since last October.
Mid-Day: The NASDAQ is Down -15.04 (-0.51%) to 2,933.53 while the Dow is also DOWN -45.37 (-0.35%) to 12,920.32.
Mid-Day Market Commentary: Stocks are turning in a lackluster performance in mid-day trading on Wednesday … amid uncertainty about the near-term outlook for the markets. The major averages are lingering near the unchanged line and are posting modest losses, off their lows for the mid-day session. The choppy trading comes as traders seem reluctant to make any significant moves following the recent strength in the markets.
Who is UP … Mid-Day:
- Aastrom (ASTM);
- Athersys (ATHX);
- Cytomedix (OTC BB: CMXI);
- Geron (GERN);
- International Stem Cell (OTC BB: ISCO);
- NeoStem (Amex: NBS);
- Opexa (OPXA);
- Pluristem (PSTI);
- Tengion (TNGN);
- ThermoGenesis (KOOL);
- Verastem (VSTM).
What’s new in the regenerative medicine/stem cell market … things to know today … NOTHING …
Register here to be notified of future Scimitar Equity articles.
